Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 9/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 9/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.36 |
| ▸ | FEN1 | P39748 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7616129 | 0.92 | PTGES2 (0.33) | ALOX5APFEN1 | |
| SCHEMBL6807452 | 0.89 | MAS1 (0.34) | AGTR1AGTR2 | |
| SCHEMBL7614979 | 0.87 | AGTR2 (0.41) | AGTR1AGTR2 | |
| SCHEMBL7616661 | 0.83 | AGTR2 (0.38) | AGTR1AGTR2 | |
| SCHEMBL7616527 | 0.82 | MAS1 (0.43) | — | |
| SCHEMBL7617557 | 0.81 | AGTR2 (0.36) | AGTR1AGTR2 | |
| SCHEMBL7617888 | 0.81 | MAS1 (0.37) | AGTR1AGTR2 | |
| SCHEMBL7690753 | 0.80 | PTGES2 (0.38) | AGTR1AGTR2 | |
| SCHEMBL7648006 | 0.80 | MAS1 (0.39) | AGTR2 | |
| SCHEMBL7616183 | 0.79 | HTT (0.42) | AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6335451-B1 | ANTIARRYTHMIA AGENTS, ANTIPROLIFERATIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-01-01 | — | — | US | claimed |
| US-6486189-B2 | TREATMENT OR PROPHYLAXIS OF AN ILLNESS CAUSED BY AN ISCHEMIC CONDITION, OR FOR THE TREATMENT OF IMPAIRED RESPIRATORY DRIVE | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-11-26 | — | — | US | disclosed |
| US-20020045761-A1 | Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | KLEEMANN HEINZ-WERNER (DE) | 2002-04-18 | — | — | US | disclosed |
| US-6335451-B1 | ANTIARRYTHMIA AGENTS, ANTIPROLIFERATIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-01-01 | — | — | US | disclosed |
| EP-0855392-A2 | Five-membered heterocycles having biphenylsulphonyl substituents, processes for the preparation thereof, their use as medicaments or diagnostic agent and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045761-A1 | Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | BAX, BCL2, TNNI3 | AGTR1 1527/4885AGTR2 1901/4885ALOX5AP 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.